Skip to main content

CDC Panel Recommends a New Shingle Vaccine

Nurse Talking with Senior Patient Provider

The Centers for Disease Control and Prevention (CDC) advisory panel voted to use a new shingles vaccine over a prior version that was thought less effective. This vote followed the Food and Drug Administration’s (FDA’s) approval of the new vaccine, Shingrix, made by GlaxoSmithKline, targeting adults over the age of 50. It was tested in 38,000 people, producing 98 effectiveness for one year, and 85 effectiveness over three years. However, more people experienced more adverse reactions to Shingrix than the prior shingles vaccine. Previously, the panel had recommended use of Zostavax, which had been the only shingles vaccine available for older adults, ages 60 years old and up. For more details, read the New York Times article.